Is idiopathic pulmonary fibrosis now treatable?

American Journal of Respiratory and Critical Care Medicine

Volumn 171, Issue 9, 2005, Pages 939-940

  Du Bois, Roland M ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BOSENTAN; CORTICOSTEROID; ETANERCEPT; GAMMA INTERFERON; PIRFENIDONE;

CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE MARKER; EDITORIAL; EXERCISE TEST; FORCED EXPIRATORY VOLUME; HUMAN; IDIOPATHIC DISEASE; LUNG FIBROSIS; MORTALITY; OXYGEN SATURATION; PRIORITY JOURNAL; PULSE OXIMETRY; SURVIVAL TIME; TOTAL LUNG CAPACITY; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; EXERCISE TEST; HUMANS; PULMONARY FIBROSIS; PYRIDONES; TREATMENT OUTCOME;

EID: 18144387938     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.2502001     Document Type: Editorial

References (15)

1. Fellrath JM, du Bois RM. Idiopathic pulmonary fibrosis/cryptogenic fibrosing alveolitis. Clin Exp Med 2003;3:65-83.
2. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;161:646-664.
3. Davies HR, Richeldi L, Walters EH. Immunomodulatory agents for idiopathic pulmonary fibrosis (Cochrane Review). In: The Cochrane Library, Issue 1. Chichester, UK: John Wiley & Sons, Ltd.; 2004.
4. Richeldi L, Davies HR, Ferrara G, Franco F. Corticosteroids for idiopathic pulmonary fibrosis. (Cochrane Review). In: The Cochrane Library, Issue 1. Chichester, UK: John Wiley & Sons, Ltd.; 2004.
5. Wells AU, Rubens MB, du Bois RM, Hansell DM. Serial CT in fibrosing alveolitis: prognostic significance of the initial pattern. Am J Roentgenol 1993;161:1159-1165.
6. Selman M, King TE. Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134:136-151.
7. Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, King TE Jr. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004;350:125-133.
8. King TE Jr, Safrin S, Starko KM, Brown KK, Noble PW, Raghu G, Schwartz DA. Analyses of efficacy end points in a controlled trial of interferon-[gamma]1b for idiopathic pulmonary fibrosis. Chest 2005;127:171-177.
9. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K. Taguchi Y, Nagai S, Itoh H, Ohi M, et al. Double blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005;171:1040-1047.
10. Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med 1999;159:1061-1069.
11. Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, Travis WD, Flint A, Toews GB, Lynch JP III, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003;168:543-548.
12. Latsi PI, du Bois RM, Nicholson AG, Colby TV, Bisirtzoglou D, Nikolakopoulou A, Veeraraghavan S, Hansell DM, Wells AU. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003;168:531-537.
13. Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:538-542.
14. Lama VN, Flaherty KR, Toews GB, Colby TV, Travis WD, Long Q, Murray S, Kazerooni EA, Gross BH, Lynch JP III, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003;168:1084-1090.
15. Yokoyama A, Kohno N, Hamada H, Sakatani M, Ueda E, Kondo K, Hirasawa Y, Hiwada K. Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998;158:1680-1684.